Innovation Theaters
* These are not official programs of the American College of Rheumatology.
EXAMPLE nr-axSpA: Breaking the Code
Exhibit Hall, Innovation Theater A
Developed and offered by UCB, Inc.
(Non-CME)
Treating Patients with PsA and AS Today & Tomorrow
Exhibit Hall, Innovation Theater B
Developed and offered by Eli Lilly and Company
(Non-CME)
SAPHNELO® (anifrolumab-fnia): A First-In-Class IFN-1 Signaling Inhibitor, Now With 4-Year Data From a Long-Term Safety and Tolerability Study
Exhibit Hall, Innovation Theater A
Developed and offered by AstraZeneca
(Non-CME)
Updated Guidance Calls for the Earlier Use of Biologics: Are You Embracing the Change?
Exhibit Hall, Innovation Theater B
Developed and offered by GSK
(Non-CME)
The First FDA-Approved Biologic for the Treatment of Polymyalgia Rheumatica: A Deep Dive
Exhibit Hall, Innovation Theater A
Developed and offered by Sanofi
(Non-CME)
Expert Perspectives: Identification and Management of Eosinophilic Granulomatosis with Polyangiitis
Exhibit Hall, Innovation Theater B
Developed and offered by GSK
(Non-CME)
COSENTYX® (secukinumab) Joint Decision Making
Exhibit Hall, Innovation Theater B
Developed and offered by Novartis Pharmaceuticals Corporation
(Non-CME)
A Clinical Approach to Hypophosphatasia
Exhibit Hall, Innovation Theater A
Developed and offered by Alexion Pharmaceuticals, Inc.
(Non-CME)
Breaking the Cycle of Recurrent Pericarditis: A Targeted Approach for Pain Relief, Inflammation Resolution, and Flare Prevention
Exhibit Hall, Innovation Theater B
Developed and offered by Kiniksa Pharmaceuticals Corp.
(Non-CME)
Holistic Care of the Immunocompromised Rheumatologic Patient – Case Analysis
Exhibit Hall, Innovation Theater A
Developed and offered by GSK
(Non-CME)
A Rheumatologist and Nephrologist Discuss Kidney Preservation in Lupus Nephritis
Exhibit Hall, Innovation Theater B
Developed and offered by Aurinia Pharma U.S.
(Non-CME)
Pioneering CAR T Cell Therapy in Autoimmune Diseases: A Fireside Chat with Dr. Georg Schett and Dr. Carl June
Exhibit Hall, Innovation Theater A
Developed and offered by Cabaletta Bio
(Non-CME)
The Inflammatory Role of the Eosinophil in EGPA
Exhibit Hall, Innovation Theater B
Developed and offered by AstraZeneca
(Non-CME)
Use of a Prescription Janus Kinase (JAK) Inhibitor for Active Ankylosing Spondylitis (AS), Including Review of a Hypothetical Patient Case
Exhibit Hall, Innovation Theater A
Developed and offered by Pfizer, Inc.
(Non-CME)
Autoimmune-Associated Interstitial Lung Disease: A Patient’s Journey, A Physician’s Perspective, and the Power of Collaborative Care
Exhibit Hall, Innovation Theater A
Developed and offered by Boehringer Ingelheim Pharmaceuticals, Inc.
(Non-CME)
TREMFYA® Efficacy, Safety, and Real-World Evidence In Adults With Active Psoriatic Arthritis
Exhibit Hall, Innovation Theater B
Developed and offered by Janssen
(Non-CME)